The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
9 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $22,169,647 in first-year total cost, median $2,205,587.
Most frequent study sections
- Special Emphasis Panel[ZDA1 IXN-O (11)]4
- Special Emphasis Panel[ZDA1 IXN-O (04)]2
- Special Emphasis Panel[ZDA1 IXN-O (06)]2
- Special Emphasis Panel[ZDA1 IXN-O (13)]1
Most frequent institutions
- UNIVERSITY OF CINCINNATI2
- ASTRAEA THERAPEUTICS, LLC1
- BIOMEDICAL RESEARCH INSTITUTE OF NEW MEX1
- INTERVEXION THERAPEUTICS, LLC1
- PUBLIC HEALTH FOUNDATION ENTERPRISES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2020 | Clinical development of an mGlu2 positive allosteric modulator to treat nicotine addiction1U01DA051077-01 | ANTHENELLI, ROBERT MCOSFORD, NICHOLAS DAVIDVELICELEBI, GONUL | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE, CA | $3,703,043 | ZDA1 |
| 2020 | Development of a Long-acting Enzyme Therapy for Treatment of Cocaine Abuse1U01DA051079-01 | ZHAN, CHANG-GUO | UNIVERSITY OF KENTUCKY, KY | $3,521,165 | ZDA1 |
| 2020 | Optimization and testing of anti-methamphetamine antibody therapy to support pivotal clinical trials and commercialization1U01DA051078-01 | GENTRY, W BROOKSSTEVENS, MISTY WARD | INTERVEXION THERAPEUTICS, LLC, AR | $3,136,427 | ZDA1 |
| 2020 | Mirtazapine for methamphetamine use disorder: drug-drug interaction study1U01DA051080-01 | COFFIN, PHILLIP O | PUBLIC HEALTH FOUNDATION ENTERPRISES, CA | $2,205,587 | ZDA1 |
| 2019 | First-In-Human Study of a Humanized Anti-Cocaine Monoclonal Antibody1U01DA048525-01 | NORMAN, ANDREW B | UNIVERSITY OF CINCINNATI, OH | $4,770,702 | ZDA1 |
| 2019 | IND-Enabling Pre-Clinical Studies to Accelerate the Clinical Development of a Humanized Anti-Cocaine Monoclonal Antibody1U01DA050330-01 | NORMAN, ANDREW B | UNIVERSITY OF CINCINNATI, OH | $1,796,316 | ZDA1 |
| 2019 | PTPRD ligands for stimulant and opiate use disorders1U01DA047713-01 | UHL, GEORGE RICHARD | BIOMEDICAL RESEARCH INSTITUTE OF NEW MEX, NM | $1,355,537 | ZDA1 |
| 2019 | Clinical Assessment of Anti-cocaine Vaccine dAdGNE in Cocaine Addicts1U01DA048524-01 | CRYSTAL, RONALD G | WEILL MEDICAL COLL OF CORNELL UNIV, NY | $539,718 | ZDA1 |
| 2018 | DEVELOPMENT OF A NOVEL DRUG CANDIDATE WITH A FIRST-in-CLASS MECHANISM FOR SMOKING CESSATION, RELAPSE and ABSTINENCE1U01DA047791-01 | ZAVERI, NURULAIN T | ASTRAEA THERAPEUTICS, LLC, CA | $1,141,152 | ZDA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.